According to guidelines for molecular diagnosis in advanced NSCLC patients, molecular testing of EGFR and BRAF mutations, ALK and ROS1 rearrangements and programmed death-ligand 1 (PD-L1) expression is considered mandatory [3, 14]. Here, EGFR is linked to non-small cell lung carcinoma.